A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced or Metastatic Her-2-Positive Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 04 Nov 2014
At a glance
- Drugs BMS 754807; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 12 Jul 2012 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 04 Mar 2012 EudraCT reports actual initiation date as Apr 2010; additional trial centre identified and inclusion, exclusion criteria amended.
- 03 Mar 2012 Planned End Date changed from 1 Mar 2012 to 1 Apr 2013 as reported by European Clinical Trials Database.